Immunoglobulin G - ADMA Biologics

Drug Profile

Immunoglobulin G - ADMA Biologics

Alternative Names: Bivigam; Immunoglobulin liquid intravenous - Biotest Pharmaceuticals; IVIG - Biotest Pharmaceuticals; IVIG - Nabi Biopharmaceuticals; NABI-IVIG

Latest Information Update: 08 Jun 2017

Price : $50

At a glance

  • Originator Nabi Biopharmaceuticals
  • Developer ADMA Biologics
  • Class Immunoglobulin isotypes
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Immunodeficiency disorders

Most Recent Events

  • 08 Jun 2017 ADMA biologics acquires Hepatitis B immune globulin, immunoglobulin G from Biotest Pharmaceuticals Corporation’s Therapy Business Unit
  • 19 Jan 2016 Immunoglobulin G licensed to Kedrion Biopharma in USA
  • 31 Jan 2013 Launched for Immunodeficiency disorders in USA (IV) - First global launch
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top